Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): Results from the ESSENCE-DIABETES Trial

Won Jang Kim; Seung Whan Lee; Seong Wook Park; Young Hak Kim; Sung Cheol Yun; Jong Young Lee; Duk Woo Park; Soo Jin Kang; Cheol Whan Lee; Jae Hwan Lee; Si Wan Choi; In Whan Seong; Bong Ki Lee; Nae Hee Lee; Yoon Haeng Cho; Won Yong Shin; Seung Jin Lee; Se Whan Lee; Min Su Hyon; Duk Won Bang; Woo Jung Park; Hyun Sook Kim; Jei Keon Chae; Keun Lee; Hoon Ki Park; Chang Bum Park; Sang Gon Lee; Min Kyu Kim; Kyoung Ha Park; Young Jin Choi; Sang Sig Cheong; Tae Hyun Yang; Jae Sik Jang; Sung Ho Her; Seung Jung Park

doi:10.1161/CIRCULATIONAHA.110.015453

Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): Results from the ESSENCE-DIABETES Trial

Won Jang Kim, Seung Whan Lee, Seong Wook Park, Young Hak Kim, Sung Cheol Yun, Jong Young Lee, Duk Woo Park, Soo Jin Kang, Cheol Whan Lee, Jae Hwan Lee, Si Wan Choi, In Whan Seong, Bong Ki Lee, Nae Hee Lee, Yoon Haeng Cho, Won Yong Shin, Seung Jin Lee, Se Whan Lee, Min Su Hyon, Duk Won BangWoo Jung Park, Hyun Sook Kim, Jei Keon Chae, Keun Lee, Hoon Ki Park, Chang Bum Park, Sang Gon Lee, Min Kyu Kim, Kyoung Ha Park, Young Jin Choi, Sang Sig Cheong, Tae Hyun Yang, Jae Sik Jang, Sung Ho Her, Seung Jung Park

Department of Medicine

Research output: Contribution to journal › Article › peer-review

106 Scopus citations

Abstract

Background-: Drug-eluting stents significantly improved angiographic and clinical outcomes compared with bare metal stents in diabetic patients. However, a comparison of everolimus-eluting stents and sirolimus-eluting stents in diabetic patients has not been evaluated. Therefore we compared effectiveness of everolimus-eluting stents and sirolimus-eluting stents in patients with diabetes mellitus. Methods and results-: This prospective, multicenter, randomized study compared everolimus-eluting stent (n=149) and sirolimus-eluting stent (n=151) implantation in diabetic patients. The primary end point was noninferiority of angiographic in-segment late loss at 8 months. Clinical events were also monitored for at least 12 months. Everolimus-eluting stents were noninferior to sirolimus-eluting stents for 8-month in-segment late loss (0.23±0.27 versus 0.37±0.52 mm; difference,-0.13 mm; 95% confidence interval,-0.25 to-0.02; upper 1-sided 95% confidence interval,-0.04; P<0.001 for noninferiority), with reductions in in-stent restenosis (0% versus 4.7%; P=0.029) and in-segment restenosis (0.9% versus 6.5%; P=0.035). However, in-stent late loss (0.11±0.26 versus 0.20±0.49 mm; P=0.114) was not statistically different between the 2 groups. At 12 months, ischemia-driven target lesion revascularization (0.7% versus 2.6%; P=0.317), death (1.3% versus 3.3%; P=0.448), and myocardial infarction (0% versus 1.3%; P=0.498) were not statistically different between the 2 groups. Major adverse cardiac events, including death, myocardial infarction, and ischemia-driven target lesion revascularization (2.0% versus 5.3%; P=0.218), were also not statistically different between the 2 groups. Conclusions-: Everolimus-eluting stents were noninferior to sirolimus-eluting stents in reducing in-segment late loss and reduced angiographic restenosis at 8 months in patients with diabetes mellitus and coronary artery disease.

Original language	English
Pages (from-to)	886-892
Number of pages	7
Journal	Circulation
Volume	124
Issue number	8
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.110.015453
State	Published - 23 Aug 2011

Keywords

coronary artery disease
diabetes mellitus
drug-eluting stent

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/CIRCULATIONAHA.110.015453

Fingerprint

Dive into the research topics of 'Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): Results from the ESSENCE-DIABETES Trial'. Together they form a unique fingerprint.

Cite this

Kim, W. J., Lee, S. W., Park, S. W., Kim, Y. H., Yun, S. C., Lee, J. Y., Park, D. W., Kang, S. J., Lee, C. W., Lee, J. H., Choi, S. W., Seong, I. W., Lee, B. K., Lee, N. H., Cho, Y. H., Shin, W. Y., Lee, S. J., Lee, S. W., Hyon, M. S., ... Park, S. J. (2011). Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): Results from the ESSENCE-DIABETES Trial. Circulation, 124(8), 886-892. https://doi.org/10.1161/CIRCULATIONAHA.110.015453

@article{d2ec2861057842618eb4d3729b75107f,

title = "Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): Results from the ESSENCE-DIABETES Trial",

abstract = "Background-: Drug-eluting stents significantly improved angiographic and clinical outcomes compared with bare metal stents in diabetic patients. However, a comparison of everolimus-eluting stents and sirolimus-eluting stents in diabetic patients has not been evaluated. Therefore we compared effectiveness of everolimus-eluting stents and sirolimus-eluting stents in patients with diabetes mellitus. Methods and results-: This prospective, multicenter, randomized study compared everolimus-eluting stent (n=149) and sirolimus-eluting stent (n=151) implantation in diabetic patients. The primary end point was noninferiority of angiographic in-segment late loss at 8 months. Clinical events were also monitored for at least 12 months. Everolimus-eluting stents were noninferior to sirolimus-eluting stents for 8-month in-segment late loss (0.23±0.27 versus 0.37±0.52 mm; difference,-0.13 mm; 95% confidence interval,-0.25 to-0.02; upper 1-sided 95% confidence interval,-0.04; P<0.001 for noninferiority), with reductions in in-stent restenosis (0% versus 4.7%; P=0.029) and in-segment restenosis (0.9% versus 6.5%; P=0.035). However, in-stent late loss (0.11±0.26 versus 0.20±0.49 mm; P=0.114) was not statistically different between the 2 groups. At 12 months, ischemia-driven target lesion revascularization (0.7% versus 2.6%; P=0.317), death (1.3% versus 3.3%; P=0.448), and myocardial infarction (0% versus 1.3%; P=0.498) were not statistically different between the 2 groups. Major adverse cardiac events, including death, myocardial infarction, and ischemia-driven target lesion revascularization (2.0% versus 5.3%; P=0.218), were also not statistically different between the 2 groups. Conclusions-: Everolimus-eluting stents were noninferior to sirolimus-eluting stents in reducing in-segment late loss and reduced angiographic restenosis at 8 months in patients with diabetes mellitus and coronary artery disease.",

keywords = "coronary artery disease, diabetes mellitus, drug-eluting stent",

author = "Kim, {Won Jang} and Lee, {Seung Whan} and Park, {Seong Wook} and Kim, {Young Hak} and Yun, {Sung Cheol} and Lee, {Jong Young} and Park, {Duk Woo} and Kang, {Soo Jin} and Lee, {Cheol Whan} and Lee, {Jae Hwan} and Choi, {Si Wan} and Seong, {In Whan} and Lee, {Bong Ki} and Lee, {Nae Hee} and Cho, {Yoon Haeng} and Shin, {Won Yong} and Lee, {Seung Jin} and Lee, {Se Whan} and Hyon, {Min Su} and Bang, {Duk Won} and Park, {Woo Jung} and Kim, {Hyun Sook} and Chae, {Jei Keon} and Keun Lee and Park, {Hoon Ki} and Park, {Chang Bum} and Lee, {Sang Gon} and Kim, {Min Kyu} and Park, {Kyoung Ha} and Choi, {Young Jin} and Cheong, {Sang Sig} and Yang, {Tae Hyun} and Jang, {Jae Sik} and Her, {Sung Ho} and Park, {Seung Jung}",

year = "2011",

month = aug,

day = "23",

doi = "10.1161/CIRCULATIONAHA.110.015453",

language = "English",

volume = "124",

pages = "886--892",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

Kim, WJ, Lee, SW, Park, SW, Kim, YH, Yun, SC, Lee, JY, Park, DW, Kang, SJ, Lee, CW, Lee, JH, Choi, SW, Seong, IW, Lee, BK, Lee, NH, Cho, YH, Shin, WY, Lee, SJ, Lee, SW, Hyon, MS, Bang, DW, Park, WJ, Kim, HS, Chae, JK, Lee, K, Park, HK, Park, CB, Lee, SG, Kim, MK, Park, KH, Choi, YJ, Cheong, SS, Yang, TH, Jang, JS, Her, SH & Park, SJ 2011, 'Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): Results from the ESSENCE-DIABETES Trial', Circulation, vol. 124, no. 8, pp. 886-892. https://doi.org/10.1161/CIRCULATIONAHA.110.015453

Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): Results from the ESSENCE-DIABETES Trial. / Kim, Won Jang; Lee, Seung Whan; Park, Seong Wook et al.
In: Circulation, Vol. 124, No. 8, 23.08.2011, p. 886-892.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES)

T2 - Results from the ESSENCE-DIABETES Trial

AU - Kim, Won Jang

AU - Lee, Seung Whan

AU - Park, Seong Wook

AU - Kim, Young Hak

AU - Yun, Sung Cheol

AU - Lee, Jong Young

AU - Park, Duk Woo

AU - Kang, Soo Jin

AU - Lee, Cheol Whan

AU - Lee, Jae Hwan

AU - Choi, Si Wan

AU - Seong, In Whan

AU - Lee, Bong Ki

AU - Lee, Nae Hee

AU - Cho, Yoon Haeng

AU - Shin, Won Yong

AU - Lee, Seung Jin

AU - Lee, Se Whan

AU - Hyon, Min Su

AU - Bang, Duk Won

AU - Park, Woo Jung

AU - Kim, Hyun Sook

AU - Chae, Jei Keon

AU - Lee, Keun

AU - Park, Hoon Ki

AU - Park, Chang Bum

AU - Lee, Sang Gon

AU - Kim, Min Kyu

AU - Park, Kyoung Ha

AU - Choi, Young Jin

AU - Cheong, Sang Sig

AU - Yang, Tae Hyun

AU - Jang, Jae Sik

AU - Her, Sung Ho

AU - Park, Seung Jung

PY - 2011/8/23

Y1 - 2011/8/23

N2 - Background-: Drug-eluting stents significantly improved angiographic and clinical outcomes compared with bare metal stents in diabetic patients. However, a comparison of everolimus-eluting stents and sirolimus-eluting stents in diabetic patients has not been evaluated. Therefore we compared effectiveness of everolimus-eluting stents and sirolimus-eluting stents in patients with diabetes mellitus. Methods and results-: This prospective, multicenter, randomized study compared everolimus-eluting stent (n=149) and sirolimus-eluting stent (n=151) implantation in diabetic patients. The primary end point was noninferiority of angiographic in-segment late loss at 8 months. Clinical events were also monitored for at least 12 months. Everolimus-eluting stents were noninferior to sirolimus-eluting stents for 8-month in-segment late loss (0.23±0.27 versus 0.37±0.52 mm; difference,-0.13 mm; 95% confidence interval,-0.25 to-0.02; upper 1-sided 95% confidence interval,-0.04; P<0.001 for noninferiority), with reductions in in-stent restenosis (0% versus 4.7%; P=0.029) and in-segment restenosis (0.9% versus 6.5%; P=0.035). However, in-stent late loss (0.11±0.26 versus 0.20±0.49 mm; P=0.114) was not statistically different between the 2 groups. At 12 months, ischemia-driven target lesion revascularization (0.7% versus 2.6%; P=0.317), death (1.3% versus 3.3%; P=0.448), and myocardial infarction (0% versus 1.3%; P=0.498) were not statistically different between the 2 groups. Major adverse cardiac events, including death, myocardial infarction, and ischemia-driven target lesion revascularization (2.0% versus 5.3%; P=0.218), were also not statistically different between the 2 groups. Conclusions-: Everolimus-eluting stents were noninferior to sirolimus-eluting stents in reducing in-segment late loss and reduced angiographic restenosis at 8 months in patients with diabetes mellitus and coronary artery disease.

AB - Background-: Drug-eluting stents significantly improved angiographic and clinical outcomes compared with bare metal stents in diabetic patients. However, a comparison of everolimus-eluting stents and sirolimus-eluting stents in diabetic patients has not been evaluated. Therefore we compared effectiveness of everolimus-eluting stents and sirolimus-eluting stents in patients with diabetes mellitus. Methods and results-: This prospective, multicenter, randomized study compared everolimus-eluting stent (n=149) and sirolimus-eluting stent (n=151) implantation in diabetic patients. The primary end point was noninferiority of angiographic in-segment late loss at 8 months. Clinical events were also monitored for at least 12 months. Everolimus-eluting stents were noninferior to sirolimus-eluting stents for 8-month in-segment late loss (0.23±0.27 versus 0.37±0.52 mm; difference,-0.13 mm; 95% confidence interval,-0.25 to-0.02; upper 1-sided 95% confidence interval,-0.04; P<0.001 for noninferiority), with reductions in in-stent restenosis (0% versus 4.7%; P=0.029) and in-segment restenosis (0.9% versus 6.5%; P=0.035). However, in-stent late loss (0.11±0.26 versus 0.20±0.49 mm; P=0.114) was not statistically different between the 2 groups. At 12 months, ischemia-driven target lesion revascularization (0.7% versus 2.6%; P=0.317), death (1.3% versus 3.3%; P=0.448), and myocardial infarction (0% versus 1.3%; P=0.498) were not statistically different between the 2 groups. Major adverse cardiac events, including death, myocardial infarction, and ischemia-driven target lesion revascularization (2.0% versus 5.3%; P=0.218), were also not statistically different between the 2 groups. Conclusions-: Everolimus-eluting stents were noninferior to sirolimus-eluting stents in reducing in-segment late loss and reduced angiographic restenosis at 8 months in patients with diabetes mellitus and coronary artery disease.

KW - coronary artery disease

KW - diabetes mellitus

KW - drug-eluting stent

UR - http://www.scopus.com/inward/record.url?scp=80052170634&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.110.015453

DO - 10.1161/CIRCULATIONAHA.110.015453

M3 - Article

C2 - 21810659

AN - SCOPUS:80052170634

SN - 0009-7322

VL - 124

SP - 886

EP - 892

JO - Circulation

JF - Circulation

IS - 8

ER -

Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): Results from the ESSENCE-DIABETES Trial

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this